Next Article in Journal
Metastasizing, Luciferase Transduced MAT‑Lu Rat Prostate Cancer Models: Follow up of Bolus and Metronomic Therapy with Doxorubicin as Model Drug
Next Article in Special Issue
Sputum-Based Molecular Biomarkers for the Early Detection of Lung Cancer: Limitations and Promise
Previous Article in Journal
Glioblastoma Stem-Like Cells—Biology and Therapeutic Implications
Previous Article in Special Issue
Tomato Lycopene and Lung Cancer Prevention: From Experimental to Human Studies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 3
Issue 2
10.3390/cancers3022667
cancers-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement question_answer thumb_up
...
textsms
...
Review

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer

by
Shih-Chieh Chang
1,
Cheng-Yu Chang
2 and
Jin-Yuan Shih
3,*
1
Department of Internal Medicine, National Yang-Ming University Hospital, Yilan 260, Taiwan
2
Department of Chest Medicine, Far Eastern Memorial Hospital, Taipei 220, Taiwan
3
Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei 100, Taiwan
*
Author to whom correspondence should be addressed.
Cancers 2011, 3(2), 2667-2678; https://doi.org/10.3390/cancers3022667
Received: 28 April 2011 / Revised: 1 June 2011 / Accepted: 7 June 2011 / Published: 10 June 2011
(This article belongs to the Special Issue Lung Cancer)
View Full-Text Download PDF

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) cases comprise approximately 85% of the lung cancer cases. Before the era of target therapy, platinum-based doublet chemotherapy only led to a median survival of 8–9 months and a one-year survival of 30%–40% in patients with advanced NSCLC. In July 2002, gefitinib, a small-molecule epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), was approved for the treatment of patients with advanced NSCLC in Japan. After the widespread use of gefitinib in the treatment of NSCLC, there have been many new studies regarding the association between the clinical anticancer efficacy of gefitinib and the somatic EGFR mutation status in patients with NSCLC. This article summarizes the role of EGFR mutations in lung cancer and the use of EGFR antagonists in the treatment of lung cancer and its associated adverse effects. View Full-Text
Keywords: epidermal growth factor receptor; tyrosine kinase inhibitors; gefitinib; erlotinib epidermal growth factor receptor; tyrosine kinase inhibitors; gefitinib; erlotinib
This is an open access article distributed under the Creative Commons Attribution License.
SciFeed

Share and Cite

MDPI and ACS Style

Chang, S.-C.; Chang, C.-Y.; Shih, J.-Y. The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer. Cancers 2011, 3, 2667-2678. https://doi.org/10.3390/cancers3022667

AMA Style

Chang S-C, Chang C-Y, Shih J-Y. The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer. Cancers. 2011; 3(2):2667-2678. https://doi.org/10.3390/cancers3022667

Chicago/Turabian Style

Chang, Shih-Chieh, Cheng-Yu Chang, and Jin-Yuan Shih. 2011. "The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer" Cancers 3, no. 2: 2667-2678. https://doi.org/10.3390/cancers3022667

Find Other Styles

Article Metrics

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop